Cargando…

Systemic immune changes accompany combination treatment with immunotoxin LMB‐100 and nab‐paclitaxel

LMB‐100 is a novel immune‐conjugate (immunotoxin) that targets mesothelin. A phase 1/2 clinical trial was conducted (NCT02810418) with primary objectives assessing the safety and efficacy of LMB‐100 ± nab‐paclitaxel. Participant blood samples were analyzed for changes in serum cytokines and circulat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pegna, Guillaume Joe, Lee, Min‐Jung, Peer, Cody J., Ahmad, Mehwish I., Venzon, David J., Yu, Yunkai, Yuno, Akira, Steinberg, Seth M., Cao, Liang, Figg, William D., Donahue, Renee N., Hassan, Raffit, Pastan, Ira, Trepel, Jane B., Alewine, Christine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	RESEARCH ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9972172/ https://www.ncbi.nlm.nih.gov/pubmed/36208017 http://dx.doi.org/10.1002/cam4.5290

Ejemplares similares

Panbinostat decreases cFLIP and enhances killing of cancer cells by immunotoxin LMB-100 by stimulating the extrinsic apoptotic pathway
por: Liu, Xiu-Fen, et al.
Publicado: (2017)

Protein Synthesis Inhibition Activity of Mesothelin Targeting Immunotoxin LMB-100 Decreases Concentrations of Oncogenic Signaling Molecules and Secreted Growth Factors
por: El-Behaedi, Salma, et al.
Publicado: (2018)

Paclitaxel synergizes with exposure time adjusted CD22-targeting immunotoxins against B-cell malignancies
por: Müller, Fabian, et al.
Publicado: (2017)

Mesothelin-Targeted Recombinant Immunotoxins for Solid Tumors
por: Hagerty, Brendan L., et al.
Publicado: (2020)

Dual B- and T-cell de-immunization of recombinant immunotoxin targeting mesothelin with high cytotoxic activity
por: Mazor, Ronit, et al.
Publicado: (2016)

Immunotoxins: From Design to Clinical Application
por: Kreitman, Robert J., et al.
Publicado: (2021)

Development of Recombinant Immunotoxins for Hairy Cell Leukemia
por: Kreitman, Robert J., et al.
Publicado: (2020)

Mesothelin-targeted immunotoxin RG7787 has synergistic anti-tumor activity when combined with taxanes
por: Kolyvas, Emily, et al.
Publicado: (2016)

Immunogenicity of Immunotoxins Containing Pseudomonas Exotoxin A: Causes, Consequences, and Mitigation
por: Mazor, Ronit, et al.
Publicado: (2020)

Mechanisms of Resistance to Immunotoxins Containing Pseudomonas Exotoxin A in Cancer Therapy
por: Dieffenbach, Michael, et al.
Publicado: (2020)

Immunotoxin Complementation of HAART to Deplete Persisting HIV-Infected Cell Reservoirs
por: Berger, Edward A., et al.
Publicado: (2010)

Megakaryocytic Potentiating Factor and Mature Mesothelin Stimulate the Growth of a Lung Cancer Cell Line in the Peritoneal Cavity of Mice
por: Zhang, Jingli, et al.
Publicado: (2014)

Efficiency of Immunotoxin Cytotoxicity Is Modulated by the Intracellular Itinerary
por: Tortorella, Lori L., et al.
Publicado: (2012)

Pseudomonas Exotoxin Immunotoxins and Anti-Tumor Immunity: From Observations at the Patient’s Bedside to Evaluation in Preclinical Models
por: Leshem, Yasmin, et al.
Publicado: (2019)

Targeting malignant B cells with an immunotoxin against ROR1
por: Baskar, Sivasubramanian, et al.
Publicado: (2012)

Interactions Between Pseudomonas Immunotoxins and the Plasma Membrane: Implications for CAT-8015 Immunotoxin Therapy
por: Bokori-Brown, Monika, et al.
Publicado: (2018)

Synergistic immunotoxin-paclitaxel combination against lymphoma
por: Müller, Fabian
Publicado: (2017)

Effect of Antigen Shedding on Targeted Delivery of Immunotoxins in Solid Tumors from a Mathematical Model
por: Pak, Youngshang, et al.
Publicado: (2014)

Quantification of recombinant immunotoxin delivery to solid tumors allows for direct comparison of in vivo and in vitro results
por: Mason-Osann, Emily, et al.
Publicado: (2015)

EGFR/EGFRvIII-targeted immunotoxin therapy for the treatment of glioblastomas via convection-enhanced delivery
por: Bao, Xuhui, et al.
Publicado: (2016)

Combination Treatments with the PKC Inhibitor, Enzastaurin, Enhance the Cytotoxicity of the Anti-Mesothelin Immunotoxin, SS1P
por: Mattoo, Abid R., et al.
Publicado: (2013)

Anti-mesothelin immunotoxin induces mesothelioma eradication, anti-tumor immunity, and the development of tertiary lymphoid structures
por: Liu, Wenlong, et al.
Publicado: (2022)

Structure and Function of the LmbE-like Superfamily
por: Viars, Shane, et al.
Publicado: (2014)

Construction of an immunotoxin, HN3-mPE24, targeting glypican-3 for liver cancer therapy
por: Wang, Chunguang, et al.
Publicado: (2016)

High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis
por: Thomas, Anish, et al.
Publicado: (2015)

Protection of the Furin Cleavage Site in Low-Toxicity Immunotoxins Based on Pseudomonas Exotoxin A
por: Kaplan, Gilad, et al.
Publicado: (2016)

nab-Paclitaxel for the treatment of pancreatic cancer
por: Kim, George
Publicado: (2017)

Necrosis of Pedunculated Lipofibroma by Nab-Paclitaxel
por: Kokubu, Hiraku, et al.
Publicado: (2023)

Methylation-Associated Partial Down-Regulation of Mesothelin Causes Resistance to Anti-Mesothelin Immunotoxins in a Pancreatic Cancer Cell Line
por: Hollevoet, Kevin, et al.
Publicado: (2015)

Efficacy and safety of nab-paclitaxel or combined nab-paclitaxel and immune checkpoint inhibitors in relapsed small-cell lung cancer
por: Wan, Rui, et al.
Publicado: (2023)

Enhanced Expression of lmb Gene Encoding Laminin-Binding Protein in Streptococcus agalactiae Strains Harboring IS1548 in scpB-lmb Intergenic Region
por: Al Safadi, Rim, et al.
Publicado: (2010)

Low serum mesothelin in pancreatic cancer patients results from retention of shed mesothelin in the tumor microenvironment
por: Zhang, Xianyu, et al.
Publicado: (2022)

Successful treatment with nab-paclitaxel after hypersensitivity reaction to paclitaxel and docetaxel()
por: de Leon, Maria C.B., et al.
Publicado: (2013)

nab-Paclitaxel dose and schedule in breast cancer
por: Martín, Miguel
Publicado: (2015)

Neoadjuvant nab-paclitaxel in the treatment of breast cancer
por: Ueno, Naoto T., et al.
Publicado: (2016)

Successful Treatment of Advanced Thymic Carcinoma with Carboplatin plus nab−Paclitaxel and Maintenance Monotherapy with nab−Paclitaxel: Two Case Reports
por: Araya, Tomoyuki, et al.
Publicado: (2020)

Combining anti-CTLA4 with RG7787, an immunotoxin targeting mesothelin, promotes tumor eradication
por: Leshem, Jasmin, et al.
Publicado: (2015)

Rituximab in addition to LMB-based chemotherapy regimen in children and adolescents with primary mediastinal large B-cell lymphoma: results of the French LMB2001 prospective study
por: Dourthe, Marie Emilie, et al.
Publicado: (2022)

First-Line Treatment with Carboplatin plus nab-Paclitaxel and Maintenance Monotherapy with nab-Paclitaxel for a Thymic Carcinoma: A Case Report
por: Funaishi, Kunihiko, et al.
Publicado: (2017)

Nab-paclitaxel: potential for the treatment of advanced pancreatic cancer
por: Al-Hajeili, Marwan, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_8qh3llt4ptgvhqm3mvv3c6uos0